Cleveland BioLabs to Present at ValueRich Small-Cap Financial Expo
26 3월 2007 - 11:00PM
PR Newswire (US)
CLEVELAND, March 26 /PRNewswire-FirstCall/ -- Cleveland BioLabs,
Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is
scheduled to present at the ValueRich Small-Cap Financial Expo to
be held at the InterContinental Miami Hotel, March 27-28, 2007.
Management of Cleveland BioLabs will give a presentation on the
Company followed by a question and answer session on March 27, at
4:05 p.m. EDT. The presentation will be broadcast live over the
Internet and archived for 60 days, thereafter. Interested parties
may register for access to the presentation by visiting the
company's website at: http://www.cbiolabs.com/ or alternatively at
http://www.visualwebcaster.com/ValueRichMiami07/reg.html .
Cleveland BioLabs currently has two lead compounds in late stages
of development. Curaxin CBLC102 is an orally administered small
molecule designed to kill tumor cells by simultaneously targeting
two key regulators of apoptosis. The Company has an ongoing Phase
II trial with CBLC102 in hormone refractory prostate cancer. The
Company's other lead compound, Protectan CBLB502, is a modified
protein of a microbe that protects cells from regulated cell death.
CBLB502 is the first compound of its kind to provide protection
from both gastrointestinal and hematopoietic (bone marrow/blood
production) radiation- induced damage. Other applications for this
technology include protection from cancer treatment side effects.
The Company recently announced that it plans to submit CBLB502 to
the Department of Defense in response to a recently published
Request for Proposal (RFP) for medical radiation countermeasures to
treat gastrointestinal effects of acute radiation syndrome. The RFP
award would provide funding for development of the countermeasure
through FDA approval, as well as a commitment to purchase,
thereafter. The ValueRich Small-Cap Financial Expo in Miami will
feature the CEOs and executive teams of 50 small-cap public
companies. The Expo offers two days of expo-style exhibition,
executive leadership business development, networking events, and
traditional financial presentations before thousands of investment
bankers, fund managers, institutional and accredited investors, and
research analysts. For more information about the Expo, please
visit http://www.vrexpo.net/. About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death
to treat cancer and protect normal tissues from exposure to
radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic Foundation, Roswell Park
Cancer Institute, ChemBridge Corporation and the Armed Forces
Research Radiobiology Institute. To learn more about Cleveland
BioLabs Inc., please visit the company's website at
http://www.cbiolabs.com/. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the
date of this press release, and involve certain risks and
uncertainties. Our actual results could differ materially from
those anticipated in these forward-looking statements as a result
of various factors. Some of the factors that could cause future
results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors"
described in our Registration Statement on Form SB-2/A filed with
the Securities and Exchange Commission on September 8, 2006.
Contact: The Global Consulting Group Rachel Levine T: (646)
284-9439 E: DATASOURCE: Cleveland BioLabs, Inc. CONTACT: Rachel
Levine of The Global Consulting Group, +1-646-284-9439, , for
Cleveland BioLabs, Inc. Web site: http://www.cbiolabs.com/
http://www.visualwebcaster.com/ValueRichMiami07/reg.html
http://www.vrexpo.net/
Copyright